July 25, 2024- BD and Quest Diagnostics announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics (CDx) intended to help select the best treatment for patients with cancer and other diseases.
Moreover, Together, BD and Quest will aim to provide the pharmaceutical industry with an end-to-end solution for CDx development. The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.
“BD has been at the forefront of flow cytometry innovation for a half-century, consistently leading advancements in this critical field,” said Steve Conly, worldwide president of Biosciences at BD. “Our collaboration with Quest underscores a shared commitment to advance personalized medicine by leveraging this technology in the development of companion diagnostics to be used alongside therapeutic options for patients.”
Also Read: BD to Acquire Edwards Lifesciences’ Critical Care Product Group for $4.2 Billion
Furthermore, Using companion diagnostics to help select a first-line therapy for cancer patients can be critical to ensuring the best outcomes and cost savings. Today’s companion diagnostic tests commonly involve technologies such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next-generation sequencing (NGS) and imaging. Healthcare providers can now use flow cytometry, an established laboratory technology applied in companion diagnostics, to rapidly analyze and sort individual cells. This enables them to understand an individual’s immune response and provides insight on how best to manage the patient to improve clinical outcomes.
“This strategic collaboration with BD will combine our expertise in developing and validating biomarkers and assays with BD’s leadership in flow cytometry to offer a fully integrated solution on a larger scale,” said William Finger, vice president and general manager, Pharma Services for Quest Diagnostics. “Together, we can bring novel companion diagnostics to market that will enable more precise health care, to potentially improve patient outcomes and reduce health care costs.”
